BLOG
FDA Warning on Xylazine: Mitigating Human Risk
FDA Warning on Xylazine: Mitigating Human Risk | by: Sumeet Singh, Founder & Chairman | Article Posted: November 6, 2023 | The U.S. Food and Drug Administration (FDA) has issued a warning regarding mitigating risks from human Xylazine exposure. FDA has not...
Recent Articles
New FDA Clarification Allows Wholesale by 503B Facilities to 503A Pharmacies
New FDA Clarification Allows Wholesale by 503B Facilities to 503A Pharmacies | by: Sumeet Singh, Founder & Chairman | Article Posted: July 5,...
Navigating the Prescription Drug Reform Act: A New Landscape for Drug Manufacturers in Florida
Navigating the Prescription Drug Reform Act: A New Landscape for Drug Manufacturers in Florida | by: Kelly DiBattista, Esq., Research Director |...
Short-Dated Drug Return Scheme Becomes Short-Dated
| Short-Dated Drug Return Scheme Becomes Short-Dated | by: Sumeet Singh, Founder & Chairman | Article Posted: July 5, 2023 | Returns in the Drug...
Alabama’s New Rule Has Massive DSCSA Implications on State Regulations
Alabama’s New Rule Has Massive DSCSA Implications on State Regulations | by: Sumeet Singh, Founder & Chairman | Article Posted: May 24, 2023 |...
FDA – OA REMS Announcement Concerning requirements to Manufacturers of Opioids
New FDA - OA REMS Announcement | by: Deneen Fumich, RPh | Article Posted: May 2, 2023 | April 21, 2022, FDA published in the Federal Register open...
Oklahoma Pharmacy Board Unanimously Approves New Rules for Shipping Mail-Order Medications
| New Oklahoma Rules for Shipping Mail-Order Medications | by: Deneen Fumich, RPh | Article Posted: April 5, 2023 | Pharma Solutions reported on...
